BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 30882264)

  • 1. Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.
    Dutz A; Agolli L; Baumann M; Troost EGC; Krause M; Hölscher T; Löck S
    Acta Oncol; 2019 Jun; 58(6):916-925. PubMed ID: 30882264
    [No Abstract]   [Full Text] [Related]  

  • 2. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
    Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
    Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
    Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting.
    Santos PMG; Barsky AR; Hwang WT; Deville C; Wang X; Both S; Bekelman JE; Christodouleas JP; Vapiwala N
    Cancer; 2019 Dec; 125(23):4278-4293. PubMed ID: 31503338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients.
    Vapiwala N; Wong JK; Handorf E; Paly J; Grewal A; Tendulkar R; Godfrey D; Carpenter D; Mendenhall NP; Henderson RH; Stish BJ; Vargas C; Salama JK; Davis BJ; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1082-1089. PubMed ID: 33539968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.
    Michalski JM; Yan Y; Watkins-Bruner D; Bosch WR; Winter K; Galvin JM; Bahary JP; Morton GC; Parliament MB; Sandler HM
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):932-8. PubMed ID: 24113055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pooled patient-reported outcomes analysis of moderately hypofractionated proton beam therapy and photon-based intensity modulated radiation therapy for low- or intermediate-risk prostate cancer.
    Lukez A; Handorf E; Mendenhall NP; Henderson RH; Stish BJ; Davis BJ; Hallman M; Horwitz EM; Vapiwala N; Wong JK
    Prostate; 2024 Mar; 84(4):395-402. PubMed ID: 38108113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer.
    Goineau A; Marchand V; Rigaud J; Bourdin S; Rio E; Campion L; Bonnaud-Antignac A; Mahé MA; Supiot S
    Radiat Oncol; 2013 Mar; 8():53. PubMed ID: 23510499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer.
    Yu JB; DeStephano DM; Jeffers B; Horowitz DP; Soulos PR; Gross CP; Cheng SK
    J Clin Oncol; 2024 Jun; 42(16):1943-1952. PubMed ID: 38507655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma.
    Hirano Y; Onozawa M; Hojo H; Motegi A; Zenda S; Hotta K; Moriya S; Tachibana H; Nakamura N; Kojima T; Akimoto T
    Radiat Oncol; 2018 Feb; 13(1):23. PubMed ID: 29426342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non-Small-Cell Lung Cancer.
    Remick JS; Schonewolf C; Gabriel P; Doucette A; Levin WP; Kucharczuk JC; Singhal S; Pechet TTV; Rengan R; Simone CB; Berman AT
    Clin Lung Cancer; 2017 Jul; 18(4):364-371. PubMed ID: 28162946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer.
    Bai M; Gergelis KR; Sir M; Whitaker TJ; Routman DM; Stish BJ; Davis BJ; Pisansky TM; Choo R
    Cancer Med; 2020 Nov; 9(21):7925-7934. PubMed ID: 32931662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
    Deville C; Jain A; Hwang WT; Woodhouse KD; Both S; Wang S; Gabriel PE; Christodouleas JP; Bekelman J; Tochner Z; Vapiwala N
    Acta Oncol; 2018 Nov; 57(11):1506-1514. PubMed ID: 30028227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.
    Kalakota K; Liauw SL
    Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts.
    Wortel RC; Incrocci L; Pos FJ; van der Heide UA; Lebesque JV; Aluwini S; Witte MG; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):680-9. PubMed ID: 27055398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.